Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study

NCT00003955 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00003955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II "Up-Front Window Study" of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
September 30, 1999
Completion date
October 31, 2009
Enrollment
77 (actual)
Sites
237

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma